Next Article in Journal
Comparative Study between Direct and Pseudomorphic Transformation of Rice Husk Ash into MFI-Type Zeolite
Previous Article in Journal
Recyclable Keggin Heteropolyacids as an Environmentally Benign Catalyst for the Synthesis of New 2-Benzoylamino-N-phenyl-benzamide Derivatives under Microwave Irradiations at Solvent-Free Conditions and the Evaluation of Biological Activity
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Molecules 2018, 23(1), 12; https://doi.org/10.3390/molecules23010012

Anticoagulants Influence the Performance of In Vitro Assays Intended for Characterization of Nanotechnology-Based Formulations

1
Nanotechnology Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
2
Department of Biochemistry, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, P.O.B. 12272, Jerusalem 91120, Israel
3
Nanomedicine Research and Education Center, Institute of Pathophysiology, Semmelweis University Nagyvárad tér 4, 1089 Budapest, Hungary
4
SeroScience Ltd., Nagyvárad tér 4, 1089 Budapest, Hungary
*
Author to whom correspondence should be addressed.
Received: 5 December 2017 / Revised: 18 December 2017 / Accepted: 20 December 2017 / Published: 21 December 2017
(This article belongs to the Section Nanochemistry)
Full-Text   |   PDF [3778 KB, uploaded 21 December 2017]   |  

Abstract

The preclinical safety assessment of novel nanotechnology-based drug products frequently relies on in vitro assays, especially during the early stages of product development, due to the limited quantities of nanomaterials available for such studies. The majority of immunological tests require donor blood. To enable such tests one has to prevent the blood from coagulating, which is usually achieved by the addition of an anticoagulant into blood collection tubes. Heparin, ethylene diamine tetraacetic acid (EDTA), and citrate are the most commonly used anticoagulants. Novel anticoagulants such as hirudin are also available but are not broadly used. Despite the notion that certain anticoagulants may influence assay performance, a systematic comparison between traditional and novel anticoagulants in the in vitro assays intended for immunological characterization of nanotechnology-based formulations is currently not available. We compared hirudin-anticoagulated blood with its traditional counterparts in the standardized immunological assay cascade, and found that the type of anticoagulant did not influence the performance of the hemolysis assay. However, hirudin was more optimal for the complement activation and leukocyte proliferation assays, while traditional anticoagulants citrate and heparin were more appropriate for the coagulation and cytokine secretion assays. The results also suggest that traditional immunological controls such as lipopolysaccharide (LPS ) are not reliable for understanding the role of anticoagulant in the assay performance. We observed differences in the test results between hirudin and traditional anticoagulant-prepared blood for nanomaterials at the time when no such effects were seen with traditional controls. It is, therefore, important to recognize the advantages and limitations of each anticoagulant and consider individual nanoparticles on a case-by-case basis. View Full-Text
Keywords: nanoparticles; liposomes; hemolysis; platelet aggregation; plasma coagulation; complement activation; leukocyte proliferation; cytokines; safety; immunotoxicity; in vitro nanoparticles; liposomes; hemolysis; platelet aggregation; plasma coagulation; complement activation; leukocyte proliferation; cytokines; safety; immunotoxicity; in vitro
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Cedrone, E.; Neun, B.W.; Rodriguez, J.; Vermilya, A.; Clogston, J.D.; McNeil, S.E.; Barenholz, Y.; Szebeni, J.; Dobrovolskaia, M.A. Anticoagulants Influence the Performance of In Vitro Assays Intended for Characterization of Nanotechnology-Based Formulations. Molecules 2018, 23, 12.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top